Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 2/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CES2 | O00748 | 2/20 | 0.39 |
| ▸ | HTR1B | P28222 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2599824 | 0.98 | EPHX1 (0.59) | EPHX1MEN1THRBHTTKMT2A | |
| SCHEMBL15510919 | 0.95 | EPHX1 (0.64) | EPHX1MEN1THRBHTTKMT2A | |
| SCHEMBL15511002 | 0.95 | EPHX1 (0.64) | EPHX1MEN1THRBHTTKMT2A | |
| SCHEMBL8979942 | 0.95 | EPHX1 (0.64) | EPHX1MEN1THRBHTTKMT2A | |
| SCHEMBL13668221 | 0.93 | EPHX1 (0.52) | EPHX1MEN1THRBHTTKMT2A | |
| SCHEMBL17974512 | 0.93 | EPHX1 (0.52) | EPHX1MEN1THRBHTTKMT2A | |
| SCHEMBL8979926 | 0.93 | EPHX1 (0.67) | EPHX1MEN1THRBHTTKMT2A | |
| SCHEMBL15279667 | 0.91 | EPHX1 (0.71) | EPHX1MEN1THRBHTTKMT2A | |
| SCHEMBL22296973 | 0.91 | EPHX1 (0.71) | EPHX1MEN1THRBHTTKMT2A | |
| SCHEMBL21634574 | 0.91 | HTT (0.52) | EPHX1MEN1THRBHTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080305986-A1 | Multimers of Peptides | CONDE FIEBOES KILLIAN WALDEMAR | 2008-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080305986-A1 | Multimers of Peptides | IAPP, NGLY1, VIP | EPHX1 4309/4885MEN1 63/4885THRB 2456/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.